Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | Determining effective combinations of immune checkpoint inhibitors for lymphoma

Stephen Ansell • 3 Oct 2015
iwNHL 2015
Hodgkin Lymphoma Non-Hodgkin Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Ibrutinib Ipilimumab Nivolumab Pembrolizumab

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Stephen M. Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the clinical development of combination approaches with immune checkpoint inhibitors for the treatment of patients with non-Hodgkin and Hodgkin lymphoma. Challenges and directions for future trials with this approach are also proposed.

More from Stephen Ansell

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
1:03
What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell • 11 Dec 2023
0:51
Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell • 11 Dec 2023
1:21
Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell • 11 Dec 2023

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals